Authors: Eyad Abuelgasim,Ann Christine Modaragamage Dona,Rajan Singh Sondh,Amer Harky First published: 28 September 2020 https://doi.org/10.1111/dth.14328 Abstract The global pandemic COVID-19 has resulted in significant global morbidity, mortality and increased healthcare demands. […]
Famotidine clinical trial shows COVID-19 symptom reduction
Authors: Dagnia Zeidlickis, Vice President, Communications | zeidlick@cshl.edu | 516-367-8455 A high dose of famotidine, commonly known as Pepcid®, was found to have beneficial effects in adult patients with coronavirus disease 2019 (COVID-19), according […]
Heart-disease risk soars after COVID — even with a mild case
Authors: Saima May Sidik 10 February 2022 Massive study shows a long-term, substantial rise in risk of cardiovascular disease, including heart attack and stroke, after a SARS-CoV-2 infection. Even a […]
Study: Myocarditis risk 37 times higher for children with COVID-19 than uninfected peers
Authors: Melissa Jenco, News Content Editor August 31, 2021 The risk of myocarditis for children under 16 years is 37 times higher for those infected with COVID-19 than those who […]
The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development
Authors: Jiong Wang andMartin S. Zand Published online by Cambridge University Press: 13 April 2020 Journal of Clinical and Translational Science>Volume 5 Issue 1 Abstract There is an urgent need for vaccines […]
A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies
Authors: Gabriela Athziri Sánchez-Zuno,1,†Mónica Guadalupe Matuz-Flores,1,†Guillermo González-Estevez,1Ferdinando Nicoletti,2Francisco Javier Turrubiates-Hernández,1Katia Mangano,2 and José Francisco Muñoz-Valle1 Int J Immunopathol Pharmacol. 2021 Jan-Dec; 35: 20587384211050199.Published online 2021 Oct 10. doi: 10.1177/20587384211050199PMCID: PMC8512237PMID: 34632844 Abstract The coronavirus disease 2019 (COVID-19) […]
Former Senior FDA Official: Manufacturers, FDA Negligent In Not Investigating Covid-19 Vaccine Risks To Heart Health
Authors: DAVID GORTLER FEBRUARY 10, 2022 Manufacturers, FDA, and CDC must investigate serious cardiovascular incidents related to the Pfizer and Moderna Covid vaccines. From day ,one the U.S. Food and […]
Long-term cardiovascular outcomes of COVID-19
Authors: Yan Xie, Evan Xu, Benjamin Bowe & Ziyad Al-Aly Nature Medicine (2022) Abstract The cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not […]
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021
Weekly / January 28, 2022 / 71(4);125–131 January 19, 2022, this report was posted online as an MMWR Early Release. Authors: Tomás M. León, PhD1; Vajeera Dorabawila, PhD2; Lauren Nelson, MPH1; Emily Lutterloh, […]